Performance
Trailing returns
| 1 day |
| -2.01% | |||
| 1 week |
| -1.08% | |||
| 4 week |
| -4.37% | |||
| 3 month | +10.95% |
| |||
| YTD | +27.84% |
| |||
| 1 year | +40.10% |
| |||
| 3 years* | +32.04% |
| |||
| 5 years* | +17.97% |
| |||
| *annualized | |||||
| Best 3 month return | +97.38% | |
| Worst 3 month return | -35.59% |
Morningstar statistics
Morningstar category: Health
| Return | Risk | Rating | |
| 3 years | High | High |
|
| 5 years | High | Above Average |
|
| 10 years | Above Average | Above Average |
|
| Overall | High | Above Average |
|
Morningstar style Learn more
| Large | |||
| Mid | |||
| Small | |||
| Value | Blend | Growth |
Key statistics
| Total assets | 5.33B | |
| Front load | - | |
| Deferred load | - | |
| Expense ratio | 0.81% | |
| Management fee | - | |
| Fund family | Fidelity Investments |
Asset allocation
| Cash | 0.43% | |
| Stocks | 99.55% | |
| Bonds | 0.00% | |
| Preferred | 0.02% | |
| Other | 0.00% |
Purchase information
| Initial | $2,500 | |
| IRA Initial | $200 | |
| AIP Initial | $2,500 |
140.56-2.89(-2.01%)
Jun 19, 4:00PM EDT
Overall Morningstar RatingTM
Description
The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.
Fund filings (PDF) »
Fund filings (PDF) »
Asset manager:
Rajiv Kaul (Started: Oct 12, 2005)
Rajiv Kaul (Started: Oct 12, 2005)
Risk
| 1 year | 3 years | 5 years | 10 years | ||
| Alpha* | 5.10 | 20.58 | 17.35 | 7.37 | |
| Beta* | 1.56 | 0.81 | 0.65 | 0.65 | |
| Mean annual return | 3.66 | 2.65 | 1.65 | 1.14 | |
| R-squared* | 44.06 | 53.80 | 41.99 | 31.88 | |
| Standard deviation | 14.88 | 17.19 | 20.73 | 18.25 | |
| Sharpe ratio | 2.95 | 1.84 | 0.94 | 0.65 | |
| * Against standard index | |||||
Top 10 holdings
| Security | Net Assets | |
| Amgen Inc (AMGN) | 15.01% | |
| Gilead Sciences Inc (GILD) | 14.43% | |
| Celgene Corporation (CELG) | 7.40% | |
| Biogen Idec Inc (BIIB) | 6.95% | |
| Vertex Pharmaceuticals (VRTX) | 4.70% | |
| Alexion Pharmaceuticals, Inc. (ALXN) | 4.51% | |
| Regeneron Pharmaceuticals, Inc. (REGN) | 4.16% | |
| Biomarin Pharmaceutical, Inc. (BMRN) | 2.78% | |
| Onyx Pharmaceuticals, Inc. (ONXX) | 2.47% | |
| Medivation, Inc. (MDVN) | 2.00% |